宜明昂科-B2024中期报告

（於中華人民共和國註冊成立的股份有限公司）股份代號：1541 中 期 報 告 24783043444546474861 2024528 202432 H 183171712–1716 Kendall Arthur Smith Kendall Arthur Smith 100015 2024729 717710 3485 8835 1541 www.immuneonco.com 20239 5 20239 5 •IMM01SIRP-Fc 20235IMM01-(CMML)II202463022ORR72.7% (16/22)CRR 27.3% (6/22)≥4ORR87.5% (14/16)CRR 37.5% (6/16)≥6ORR84.6% (11/13)CRR46.2% (6/13) 20236IMM01(MDS)II20246 3051(ORR)64.7% (33/51)(CRR)33.3% (17/51)≥4ORR85.3% (29/34)CRR 50.0% (17/34)≥6ORR89.7% (26/29)CRR 58.6% (17/29)202462024ASCO 202312IMM01PD-1(R/R)(cHL)II20246 30338(CR)14(PR)ORR 66.7%CRR 24.2%202462024ASCO 20244IMM01PD-(L) 1cHLIII20247 1 20245IMM01(HRMDS)IIIIND 20246IMM01-(CMML)IIIIND •IMM0306 (CD47CD20) 20236IMM0306R/R CD20B(B-NHL)Ib/IIaIb1.6mg/kg2.0 mg/kg1120246 30R/R(FL)(MZL)1.6mg/kgIMM030620Ib113CRFL7PR 5 FL 2 MZLORRCRR90.9%27.3%202476IIaR/R FL4CR 2 PRORRCRR100%66.7% •IMM2510 (VEGFPD-L1) 20239IMM2510 I33II(RP2D)IMM2510I20246 30PRSD15% 202311IMM2510Ib/II20246 30PR 202310IMM2510IMM27MIINDIMM2510–002IMM2510IMM27MR/RIb/II202472024724 •IMM27M (CTLA-4 ADCC+) 20239IMM27M IIMM27MRP2DPR •IMM2520 (CD47PD-L1) 20233IMM2520I20246 3024IMM2520PRSD10%2024 INDIND •IMC-002 (SLE)(NMOSD)IND •IMC-001 IMC-001IND •IMC-003ACTRIIA (PAH)CMC •IMC-004ACTRIIA  20248 1SynBioTx Inc.SynBioTxInstil Bio, Inc. (NASDAQ: TIL)SynBioTxPD-L1xVEGFIMM2510CTLA-4(ADCC+) IMM27M15352120248 1822911 •20236 30128.17.0%20246 30119.1(i)11.7CRO(ii)9.020246 30(i)7.2(ii)CMC4.6IMM0306IMM2510 CMC •20246 30165.820236 30170.85.09.0 •120236 30115.84.920246 30120.7 2015Drug-by-Design (1)IND11 (2) (3)IMM01(cHL) MDSAMLCMML-B-NHLBSTScHLFLMZLINDCMCADCCTNBCNSCLCHCCSLELNMNNMOSDMGPAH •IMM01SIRP-Fc IMM01CD47SIRP-FcIgG1 FcIMM01—CD47/SIRPFcIMM01CD47(RBC)IMM01IMM01 o ◆202311FDAIMM01CMML ◆20236IMM01II5720246 3051ORR64.7%(33/51)33.3%(17/51)CR15.7%(mCR+HI)3.9%(HI)11.8%(mCR)≥4ORR85.3% (29/34)CRR 50.0% (17/34)≥6ORR89.7%(26/29)CRR 58.6% (17/29)≥31.8%IMM01 ◆20245IMM01MDSIII(IMM01–009) ◆20235IMM01CMMLII2420246 3022ORR72.7%(16/22)27.3%(6/22)CR13.6%(mCR+HI)4.5%(HI)27.3%(mCR)≥4ORR87.5% (14/16)CRR37.5% (6/16)≥6ORR84.6% (11/13)CRR 46.2% (6/13)IMM01CMMLIMM01CMML ◆20245IMM01CMMLIII(IMM01–010) o ◆20231 19IMM01PD-1R/R cHLII202312II20246 3033cHL R/R338CR14PRORR66.7%CRR 24.2%(TRAE) ◆2024II20244IMM01PD-(L) 1cHLIIIIII20247 1 ◆20246 30 IMM01 o ◆20231Ib/IIaINDIMM01MM o ◆IMM01CD47/SIRPIMC-001(IMM01)IND 18A.08(3)IMM01 •IMM0306 (CD47CD20) IMM0306CD47CD20CD47CD20-IMM0306CD47ADCCIgG1 FcADCPADCC o ◆20246 3048CD20RP2D2.0 mg/kg0.8 mg/kg2 mg/kg5CR5 PR 11 SDIMM0306 ◆I2023IIII o ◆20236IMM0306R/R CD20B-NHLIb/IIaIb1.6mg/kg2mg/kg11IIa820246 30R/R FLMZL1.6mg/kgIMM030620Ib113CRFL7PR 5 FL 2 MZLORRCRR90.9%27.3%202476IIaR/R FL4CR 2 PRORRCRR100%66.7%IMM0306Ib o ◆IMM0306B20246IND •IMM2510 (VEGFPD-L1) IMM2510–VEGFPD-L1VEGFPD-L1 IMM2510TIMM2510FcADCC/ADCP o ◆20239IMM2510I33RP2D20246 30IMM2510 I20246 30PRSD15%IMM2510 ◆202311IMM2510 Ib/II20246 30PR o ◆202311IMM2510IIIND oIMM27M ◆202310IMM2510IMM27MIINDIMM2510–002R/RIMM2510+IMM27M Ib/II202472024724 •IMM27M (CTLA-4 ADCC) IMM27MCTLA-4ADCCCTLA-4TCD80/CD86TCTLA-4CTLA-4CD80/CD86T 20239IMM27M IIMM27MRP2D2024630I2PR3SDIMM27M •IMM2520 (CD47PD-L1) IMM2520CD47PD-L1IMM2520ADCCIgG1FcPD-L1NIMM01CD47CD47ADCCIgG1 FcADCPADCC 20233 23IMM2520I0.1 mg/kg202463024IMM252020246 30PR2SD10%2024I •IMM2902 (CD47HER2) IMM2902CD47HER2NCD47IMM2902ADCCIgG1FcADCPADCC 20222IMM2902HER2HER2Ia/Ib85.0 mg/kg HER2HER22022620227 •IMM47 (CD24) IMM47CD24CD24CD24IMM47CD24/Siglec-10TADCCIgG1FcIMM47ADCPADCCM1IMM47TCD24/Siglec-10T20231012IMM47INDIMM47IND 20239IMM47 I IMC-002 (IMM0306) IMC-00247 (CD47)20 (CD20)20246(SLE)(NMOSD)IND IMC-001 (IMM01) IMC-00147 (CD47)SIRP-FcIMC-001 (IMM01)IND •IMC-003 (ACTRIIA) IMC-003ACTRIIAsotaterceptPAHCMCIND •IMC-004 (ACTRIIA) IMC-004ACTRIIA •IMM67 IMM67IMM67IMM67CMC2025 18A.08(3)IMM0306IMM2510 IMM27M IMM2520 IMM2902 IMM47IMC-002IMC-001 IMC-003 IMC-004 IMM67 20248 1SynBioTx Inc.SynBioTxInstil Bio, Inc. (NASDAQTIL)SynBioTxIMM2510IMM27M 15352127018 2024 18A.08(3) 202420236 3077,00086,000 20236 306.420246 304.31.60.4 20236 306.120246 3019.53627.46.2 CMC (i)CMCCROCDMOCMC(ii)(iii)(iv)(v)(vi)(vii) 20236 30128.17.0%20246 30119.1(i)11.7CRO(ii)9.020246 30(i)7.2(ii)CMC4.6IMM0306IMM2510CMC 20236 3041.327.1%20246 3030.120246 30 20236 300.620246 301.4 202320246 30 20236 30170.820246 30165.8 20246 30513.0202312 31608.6 20246 30582.6266.2246.869.520246 30119.845.33.571.0 20246 30123.020236 30132.49.4 20246 3040.320236 3038.4 20246 3020236 3025.621.5 20246 3090.0 20246 3019.2%202312 3114.4%4.8%26.0 20246 3086.0202312 3160.020246 303.00%3.60% 202312 3114.820246 3011.7 20246 300.2202312 316.0 20246 30 20246 30 20239 1820239152023920202311 102,600,000826,000956,000930,0001.5%4.5%20246 30126,512,00046,918,00046,386,00046,373,00020246 305%20239 1320243 25 20246 3015020246 3060.8202363080.120246 30 20211 31202112 20—— C.— 4. 20246 30XV(i)XV78(ii)352(iii) (1)H (2)20246 30374,157,695145